Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis

Abstract

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis (Protocol)

Topical interferon alpha-2b is a proper alternative for management of adenoviral keratitis: A case report

“…One-year follow-up showed that the 60% size and number of SEIs were decreased after six-month administration of tacrolimus ointment or drops and were eliminated in 32%. The visual acuity was improved significantly following the treatment procedure [17,18]. Stopping the drug administration for seven months caused a recurrence of almost 19% of the eyes [18].…”

“…The visual acuity was improved significantly following the treatment procedure [17,18]. Stopping the drug administration for seven months caused a recurrence of almost 19% of the eyes [18]. Interferon-b, an immunomodulator secreted by virally infected cells, may act by inducing an antiviral state or modulating the immune response [19].…”